• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Timber Pharmaceuticals Inc.

    11/29/23 11:10:14 AM ET
    $TMBR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TMBR alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-37411
    Issuer: Timber Pharmaceuticals, Inc.
    Exchange: NYSE AMERICAN LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 1098 Hamilton Court
    Menlo Park CALIFORNIA 94025
    Telephone number: (650) 889-5020
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, NYSE AMERICAN LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-11-29 By Emily Fuhrman Analyst, Regulation
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TMBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMBR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TMBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

      WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the "NYSE Regulation") has determined to immediately suspend trading in the Company's common stock from NYSE American, LLC (the "NYSE American"). As previously disclosed, the NYSE Regulation notified Timber on November 21, 2023 that, as a result of the voluntary bankruptcy petitions filed under Chapter 11 of the United States Bankruptcy Code by the Company and certain of its

      11/29/23 5:26:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American

      WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware. At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debt

      11/28/23 5:21:07 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

      WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the "NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, on June 28, 2023, the Company received written notice from the NYSE American that the Company was not in compliance with Sections 1003(a)(i)

      9/18/23 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Timber Pharmaceuticals Inc.

      SC 13G - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      8/15/22 6:01:57 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/14/22 9:40:54 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/4/22 3:39:18 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    SEC Filings

    See more
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/26/24 8:00:46 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/22/24 7:21:51 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      12/22/23 4:12:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

      LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. "Michael is a successful pharma industry leader whose extensive involvement in drug repurposing and his passion for developing and commercializing innovative products that positively impact patients' lives will prove to be invaluable as we advance our three lead clinical assets," stated Dr. Roddy Carter, Chairman of the Board of Acasti. "We anticipate benefitting from his perspective and broad experience." Mr. Derby brings more than two decades of experience and a proven track record wit

      3/25/22 7:30:00 AM ET
      $ACST
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors

      - Edward J. Sitar appointed as Lead Independent Director of the Board - - Company establishes Science and Technology Committee to be chaired by Dr. David Cohen - Basking Ridge, NJ, April 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Chief Executive Officer John Koconis has been appointed as Chairman of the Board of Directors. The Company also announced that Edward J. Sitar has been appointed as Lead Independent Director of the Board and David Cohen, M.D., will

      4/23/21 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

      Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical Officer. Dr. Mendelsohn assumes the roles and responsibilities of Amir Tavakkol, Ph.D., who will be stepping down as the Company’s Chief Scientific Officer.  “We are pleased to welcome Dr. Mendelsohn to our management team. Dr. Mendelsohn

      1/25/21 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Koconis John was granted 70,385 shares, increasing direct ownership by 17,596% to 70,785 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:46:54 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Mendelsohn Alan was granted 35,193 shares, increasing direct ownership by 17,596% to 35,393 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:45:20 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lucchese Joseph was granted 35,193 shares

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:43:35 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Financials

    Live finance-specific insights

    See more
    • Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

      - Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial - WARREN, NJ, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2022. John Koconi

      3/31/23 4:28:34 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

      -Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third quarter of 2022, ended September 30, 2022. John Koconis, Chairman and Chie

      11/14/22 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

      Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022  BASKING RIDGE, NJ, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter of 2022, ended March 31, 2022. John Koconis, Chairman and Chief Executive Officer of Timber, commented, "Timber's lead asset, TMB-001, continues to progress following the receipt of Fast Track designation late last month, w

      5/12/22 4:10:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care